SCHEMBL29684231

SCHEMBL29684231

CC(=O)OC(C(=O)O)c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
CYP3A4 P08684 1/20 0.49
KDM4E B2RXH2 1/20 0.47
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
HSD17B10 Q99714 1/20 0.42
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
CNR2 P34972 1/20 0.41
MTOR P42345 1/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043993 1.00 ALDH1A1 (0.49) ALDH1A1CYP3A4KDM4EHDAC4HDAC7
SCHEMBL23462029 0.86 ALDH1A1 (0.44) ALDH1A1CYP3A4KDM4EHDAC4HDAC7
SCHEMBL29975353 0.86 ALDH1A1 (0.44) ALDH1A1CYP3A4KDM4EHDAC4HDAC7
SCHEMBL17724503 0.83 KDM4E (0.60) ALDH1A1KDM4EHDAC4HDAC7HDAC5
SCHEMBL23042908 0.83 ALDH1A1 (0.42) ALDH1A1CYP3A4KDM4ECES2CES1
SCHEMBL31736106 0.83 ALDH1A1 (0.42) ALDH1A1CYP3A4KDM4ECES2CES1
SCHEMBL11350399 0.82 CYP3A4 (0.50) ALDH1A1CYP3A4HSD17B10TSHRLMNA
SCHEMBL1286155 0.81 ALDH1A1 (0.70) ALDH1A1CYP3A4KDM4EHSD17B10TSHR
SCHEMBL628737 0.81 ALDH1A1 (0.70) ALDH1A1CYP3A4KDM4EHSD17B10TSHR
SCHEMBL493954 0.81 ALDH1A1 (0.70) ALDH1A1CYP3A4KDM4EHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473296-B2 Perk inhibiting compounds HIBERCELL, INC. (US) 2025-11-18 US disclosed
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds HIBERCELL, INC. (US) 2025-06-17 US disclosed
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 US disclosed
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS HIBERCELL, INC. 2022-11-03 US disclosed
US-20220332722-A1 PERK INHIBITING COMPOUNDS HIBERCELL, INC. 2022-10-20 US disclosed
CN-115003296-A Compounds and methods for treating cystic fibrosis 弗拉特利发现实验室有限责任公司 2022-09-02 CN disclosed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 EP disclosed
EP-4021893-A1 PERK INHIBITING COMPOUNDS Hibercell, Inc. (US) 2022-07-06 EP disclosed
CN-114710956-A PERK-INHIBITING PYRROLOPYRIMIDINE COMPOUNDS 希伯塞尔股份有限公司 2022-07-05 CN disclosed
CN-114585606-A PERK inhibiting compounds 希伯塞尔股份有限公司 2022-06-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332722-A1 PERK INHIBITING COMPOUNDS ATF4, EEF2K, ERN1 ALDH1A1 2734/4885CYP3A4 4465/4885KDM4E 2977/4885
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS EEF2K, ATF4, MAPKAPK2 ALDH1A1 2477/4885CYP3A4 3991/4885KDM4E 2321/4885
US-20220348583-A1 PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS MAPKAPK2, MAPK4, MAP3K5 ALDH1A1 2619/4885CYP3A4 3599/4885KDM4E 3007/4885
US-12331054-B2 Perk inhibiting imidazolopyrazine compounds MAPKAPK2, MAPK4, MAP3K5 ALDH1A1 2619/4885CYP3A4 3599/4885KDM4E 3007/4885
US-12473296-B2 Perk inhibiting compounds MAPK1, ERN1, MAP3K20 ALDH1A1 1102/4885CYP3A4 2620/4885KDM4E 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.